BNTX logo

BioNTech SE (BNTX)

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell...

NASDAQHealthcareBiotechnologyUSA

公司簡介

股票程式碼
BNTX
ISIN程式碼
US09075V1026
貨幣
US Dollar (USD)
IPO日期
2019-10-10

聯絡資訊

公司地址
An der Goldgrube 12, Mainz, Germany, 55131
聯絡電話
49 6131 9084
公司網站
https://www.biontech.de
財年結束
December

財務亮點

市值
$999,999.99
毛利潤(TTM)
$999,999.99
資產回報率(TTM)
-4.18%
EBITDA
$-999,999.99
收入(TTM)
$999,999.99